Vivos Therapeutics Files 8-K on Financials

TL;DR

Vivos Therapeutics dropped an 8-K detailing financial condition and results. Check it out.

AI Summary

Vivos Therapeutics, Inc. filed an 8-K on March 29, 2024, reporting on events as of March 28, 2024. The filing pertains to Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The company, formerly Vivos BioTechnologies, Inc., is incorporated in Delaware and headquartered in Littleton, Colorado.

Why It Matters

This 8-K filing provides updates on Vivos Therapeutics' financial condition and results of operations, which are crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a standard 8-K reporting routine financial and operational information, not indicating any immediate or significant new risks.

Key Players & Entities

• Vivos Therapeutics, Inc. (company) — Registrant
• Vivos BioTechnologies, Inc. (company) — Former company name
• March 28, 2024 (date) — Date of earliest event reported
• March 29, 2024 (date) — Filing date
• Littleton, Colorado (location) — Principal executive offices location

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share VVOS The NASDAQ Stock Mar

Filing Documents

• form8-k.htm (8-K) — 36KB
• ex99-1.htm (EX-99.1) — 170KB
• 0001493152-24-011834.txt ( ) — 392KB
• vvos-20240328.xsd (EX-101.SCH) — 3KB
• vvos-20240328_lab.xml (EX-101.LAB) — 33KB
• vvos-20240328_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 7921 Southpark Plaza , Suite 210 Littleton , Colorado 80120 (Address of principal executive offices) (Zip Code) (844) 672-4357 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share VVOS The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 2.02. Results of Operations and Financial Condition. On March 28, 2024, Vivos Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated March 28, 2024, announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIVOS THERAPEUTICS, INC. Dated: March 28, 2024 By: /s/ Bradford Amman Name: Bradford Amman Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR